Cambridge biotechnology teams often work under demanding scientific and commercial timelines. A target may need to be validated, an assay may need a reliable reagent, or a therapeutic research program may require functional antibody candidates before the next internal decision point. In each case, the value of an antibody depends on more than whether it binds an antigen.
Precision Antibody provides scientist-led, fully human monoclonal antibody development for Cambridge biotech, biopharmaceutical, diagnostic, academic, and translational research teams. Our approach begins with the intended application. We consider the target, antigen format, desired biological activity, screening strategy, characterization needs, and downstream use before defining the development plan.
For suitable projects, our fully human monoclonal antibody program follows an approximately 60-day development pathway. The exact schedule depends on antigen readiness, screening complexity, functional assay requirements, and the agreed deliverables. Laboratory work is performed at our facility in Columbia, Maryland, while project planning, milestone reviews, data discussions, and scientific coordination can be managed efficiently with teams throughout Cambridge and Greater Boston.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there?
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
A successful antibody program starts with a clear definition of what the final antibody must do. Some projects require a highly specific binder for a research assay. Others require a candidate that blocks a receptor interaction, recognizes a native cell surface target, internalizes after binding, or produces a measurable response in a functional system.
We design each project around those intended outcomes. This helps align antigen selection, immunization, screening, clone selection, and characterization with the actual research objective.
An antibody that performs well in an ELISA may not recognize the same target in its native conformation. A clone with strong apparent binding may not provide the specificity, affinity, neutralization, internalization, or cell-based activity required by the program.
Application-specific development addresses this risk early. Before work begins, we discuss questions such as:
These decisions influence the development strategy and help reduce the risk of selecting clones that bind under one condition but fail in the intended application.
Our development process is collaborative. Scientists are involved in the early review of the target, antigen, assay requirements, and desired deliverables. Projects are then managed through defined milestones so that key findings can be discussed before the program advances.
Cambridge teams can work with us remotely while maintaining clear visibility into project progress. Scientific discussions, data reviews, and milestone decisions do not require a local laboratory presence. All antibody development work is performed in Columbia, Maryland.
Fully human monoclonal antibody development is the process of generating antigen-specific monoclonal antibodies with human immunoglobulin sequences. These antibodies are developed for research programs that require human antibody candidates without first generating a conventional nonhuman antibody and then completing a separate humanization step.
Precision Antibody uses TC mouse technology for fully human monoclonal antibody development. These mice carry human immunoglobulin genetic material and can produce fully human IgG responses following immunization. Antigen-specific antibody-producing cells can then be used in hybridoma generation, screening, clone selection, sequencing, and downstream characterization.
The result is a development pathway that combines an in vivo immune response with established monoclonal antibody screening and cloning methods.
Fully human and humanized antibodies are not the same.
A fully human monoclonal antibody is generated with human immunoglobulin sequences from the beginning of the discovery process. In a transgenic mouse platform, the animal mounts an immune response using introduced human antibody genetic material.
This approach can provide antigen-specific human IgG candidates without requiring the variable regions of a mouse antibody to be redesigned later.
A humanized antibody usually begins as an antibody generated in a nonhuman species. Selected binding regions are then transferred into a largely human antibody framework through engineering.
Humanization can be appropriate for many programs, but it adds another development stage. Additional testing may also be needed to confirm that the engineered antibody retains the desired affinity, specificity, stability, and functional behavior.
The appropriate approach depends on the target, project stage, available starting material, required timeline, and downstream research plan.
Fully human antibody candidates are often considered when a research team wants to begin with human antibody sequences while evaluating target binding and biological function. This may help streamline early discovery by reducing reliance on a later humanization stage.
However, a fully human sequence does not automatically make an antibody suitable for therapeutic development. Candidate selection still requires careful evaluation of factors such as:
Our role is to support antibody discovery and preclinical research. Precision Antibody products and services are intended for research use. They are not supplied for direct therapeutic, diagnostic, investigational, or clinical use.
Each project is shaped by the target and intended application. Although project details vary, the development pathway generally includes consultation, antigen review, immunization, hybridoma generation, screening, clone selection, sequencing, and delivery.
The first stage defines the scientific objective and identifies the information needed to design an appropriate program.
We review the available target information, antigen format, sequence, purity, presentation, and biological context. Depending on the program, the antigen may be a purified protein, peptide, recombinant construct, cell-associated target, or another suitable preparation.
The immunogen should reflect the intended target as closely as practical. Antigen quality and presentation can influence the diversity, specificity, and relevance of the resulting antibody response.
We also discuss how the antibody will be evaluated. This includes the primary screening method, confirmation assays, control materials, desired cross-reactivity, and any functional requirements.
When a functional assay is available, it may be incorporated into candidate evaluation at the appropriate stage. The specific assay plan depends on feasibility, available materials, project scope, and the biological question being addressed.
TC mouse technology enables the generation of fully human IgG responses following immunization with the selected antigen.
The immunization strategy is developed around the antigen, target biology, and desired response. Immune response monitoring may be used to assess antigen recognition and help guide progression toward cell collection and hybridoma generation.
The purpose is not simply to obtain a measurable immune response. The goal is to generate a useful pool of antigen-specific antibody-producing cells for downstream screening.
An in vivo immune response provides the opportunity for immune selection and affinity maturation. This can support the generation of diverse antigen-specific candidates before hybridoma screening and clone selection.
The final candidate profile still depends on the target, immunogen, immune response, screening design, and the criteria used to advance clones.
Following an appropriate immune response, antibody-producing cells are used for hybridoma generation. Hybridoma cultures are then evaluated to identify antigen-reactive candidates.
Primary screening is designed to identify antibodies that recognize the intended antigen. Depending on the project, this may include comparison with related proteins, irrelevant controls, alternate antigen formats, or target-negative samples.
The screening plan should reflect the biological and technical risks of the program. A highly conserved target, for example, may require a different specificity strategy than a unique recombinant antigen.
Controls help distinguish true target recognition from nonspecific or format-dependent binding. The most useful controls are selected during project planning and may include:
Relevant controls improve the quality of candidate selection and provide more informative data than a single positive binding measurement.
Binding data can identify candidates, but functional screening helps determine whether those candidates perform in the intended biological context.
For some therapeutic research programs, the desired antibody must block a ligand, receptor, enzyme, pathogen component, or signaling interaction. Candidate evaluation may therefore include a suitable inhibition or neutralization assay when the required system is available.
The assay should be selected because it reflects the research objective, not simply because it produces a convenient signal.
Other programs may require antibodies that internalize after target engagement, activate a receptor, alter a cellular pathway, or recognize a native cell surface structure.
These behaviors cannot always be predicted from standard binding assays. Where appropriate, cell-based or mechanism-related testing can provide an additional layer of candidate differentiation.
Promising hybridomas are advanced through cloning and confirmation so that monoclonal candidates can be evaluated consistently.
Variable region sequencing identifies the antibody heavy and light chain variable sequences associated with selected clones. Sequence information supports clone documentation, recombinant expression, comparison of candidate diversity, and downstream engineering work.
Recombinant expression can be used to confirm antibody performance outside the original hybridoma context and to generate additional material for characterization or functional studies.
The required format, expression scale, and purification level depend on the project.
Final deliverables are defined in the project agreement. Depending on scope, they may include antibody material, selected hybridoma clones, sequence information, screening data, and related project documentation.
Under applicable project agreements, developed clones are transferred to the customer, and Precision Antibody does not retain ownership of the completed clones. Ownership, delivery, confidentiality, and service terms should always be confirmed in the executed agreement.
Precision Antibody offers an approximately 60-day fully human monoclonal antibody development pathway for suitable projects. The timeline is a planning framework, not a guarantee that every target, assay, characterization activity, and production request will be completed within exactly 60 days.
The development schedule generally begins after project scope, antigen requirements, contractual terms, and starting materials are confirmed. The pathway may include immunization, immune response assessment, hybridoma generation, primary screening, clone selection, and agreed development milestones.
The exact endpoint included within the approximately 60-day period should be defined during project planning. Additional work such as advanced functional testing, extensive characterization, recombinant production, stability studies, or gram-scale manufacturing may require more time.
Several factors can influence the schedule:
Delays in antigen production, purification, shipment, or quality review can affect the project start date.
Membrane proteins, conserved targets, low-immunogenicity antigens, and structurally sensitive epitopes may require additional strategy development.
Programs with multiple counterscreens, species comparisons, cell-based assays, or functional requirements may require a broader evaluation process.
A functional assay that is already established may be integrated more efficiently than an assay that must first be transferred, adapted, or developed.
Additional cloning, sequencing, recombinant expression, or repeat testing may be appropriate before final selection.
Purified antibody production beyond initial screening quantities can extend the overall delivery schedule.
A clear definition of milestones and deliverables helps prevent uncertainty and allows the timeline to reflect the actual scientific objective.
A fully human antibody project can be structured around the client’s target, intended use, available materials, and desired endpoint. The exact scope is agreed before work begins.
A typical project may include the following stages:
Depending on scope, project deliverables may include:
Not every deliverable is included automatically. The development plan should identify which outputs are essential for the next stage of the client’s program.
Additional services can help Cambridge research teams move from initial clone selection into deeper candidate evaluation.
Affinity and binding kinetics may be evaluated using methods such as Octet or Biacore, depending on the antibody, antigen, assay format, and project requirements.
These measurements can provide information about association, dissociation, and overall binding behavior. They should be interpreted alongside specificity and functional data rather than used as the sole basis for candidate selection.
Epitope binning can help identify antibodies that recognize different target regions or compete for overlapping binding sites. This is useful when a program needs candidate diversity, paired antibodies, mechanism-related differentiation, or multiple options for downstream testing.
Selected antibodies can be produced and purified at scales appropriate for research, characterization, assay development, and preclinical evaluation. Production scope depends on the antibody format, expression system, quantity, purity requirements, and project timing.
The strongest binder is not always the best antibody for the program. Candidate selection should reflect what the antibody must accomplish under relevant experimental conditions.
A candidate may bind strongly to an immobilized antigen but fail to recognize the target on a cell. Another antibody may show moderate apparent affinity yet produce the most useful biological effect because it recognizes a functionally important epitope.
Differences in antigen folding, orientation, modification, density, and assay format can all affect performance. This is why screening should progress from simple identification toward increasingly relevant confirmation.
An application-specific screening plan may include several layers:
The exact sequence depends on the target and the decisions the research team needs to make. Not every program requires every assay, but each assay should have a clear purpose.
For therapeutic research, candidate selection may consider more than one property. A balanced panel may include antibodies with different epitopes, affinities, mechanisms, sequences, or functional profiles.
Selecting several well-differentiated candidates can provide more flexibility for later work such as recombinant expression, format conversion, developability assessment, mechanism studies, and preclinical evaluation.
Cambridge organizations range from early-stage biotechnology companies to established biopharmaceutical teams, academic laboratories, research hospitals, and specialized diagnostic groups. Their antibody needs differ, but many face the same challenge: obtaining candidates that are relevant to the intended experiment or development decision.
Therapeutic research programs may need antibodies that block, activate, internalize, neutralize, or selectively recognize a disease-related target.
We support early discovery by helping define the desired candidate profile and designing development and screening around that profile. Our work can provide fully human monoclonal antibodies for further research, characterization, engineering, and preclinical evaluation.
Immunology and immuno-oncology programs often involve complex receptors, ligands, signaling pathways, immune cell populations, and target-dependent functions.
These programs may benefit from screening strategies that evaluate native target recognition, cell binding, pathway modulation, or functional activity in addition to purified antigen binding.
Cell surface targets can present challenges related to conformation, extracellular domain structure, expression level, purification, and native presentation.
A project may require careful antigen design, cell-based confirmation, relevant counterscreens, or multiple screening formats. Early discussion of these risks helps shape a more practical strategy.
Fully human antibodies may also support biomarker research, assay development, and diagnostic research applications. Depending on the intended assay, candidate evaluation may focus on specificity, pair compatibility, sensitivity, epitope diversity, reproducibility, or recognition of native samples.
Any resulting antibodies are supplied for research use and are not provided for direct diagnostic use.
Early-stage Cambridge companies may not maintain every antibody discovery, screening, sequencing, and production capability internally. Outsourcing can provide access to specialized workflows while allowing the internal team to remain focused on target biology, program strategy, and decision making.
A focused external program can also help a company define clear milestones before committing resources to broader downstream development.
Fully human antibody generation may be one part of a broader research program. Teams evaluating additional species, antibody formats, anti-idiotype programs, or related development pathways can review our broader custom antibody development services to understand how complementary capabilities may support their objectives.
Recombinant expression supports sequence-confirmed production, format evaluation, and generation of additional research material. It can also help confirm that candidate behavior is maintained after expression outside the original hybridoma.
Production can be scaled according to research needs, from smaller characterization quantities to larger purified batches.
Anti-idiotype antibodies can support pharmacokinetic and anti-drug antibody assay development during preclinical research. The desired anti-idiotype profile may vary depending on whether the reagent should recognize the drug antibody specifically, compete with antigen binding, or support a particular assay format.
These projects require careful immunogen design, screening, and specificity confirmation.
Characterization may include affinity measurement, binding kinetics, specificity testing, epitope analysis, functional testing, sequence confirmation, and stability-related evaluation.
The appropriate package depends on the decisions that must be made next. Early discovery teams may need a focused comparison of several clones, while more advanced programs may require deeper evaluation of a smaller candidate set.
Cell line support and banking can help preserve selected clones, improve continuity, and provide material for future antibody production. Banking scope, testing, storage, and transfer requirements should be agreed as part of the project.
Outsourcing antibody development is not simply a capacity decision. It can also be a way to access focused scientific experience, established workflows, and an independent perspective on project design.
A specialized provider can help identify risks that may not be obvious at the start of a program. These may include antigen presentation, assay artifacts, conserved epitopes, cross-reactivity, weak immunogenicity, or a mismatch between the screening format and the final application.
Addressing these issues before immunization and screening can make the project more informative.
Establishing an internal monoclonal antibody workflow requires animal work, cell culture, fusion capability, screening infrastructure, cloning, sequencing, production, and experienced personnel.
For teams that do not need this infrastructure continuously, an external development program can provide access to these capabilities without requiring the organization to build and maintain the complete platform.
Scientific communication matters when project decisions depend on evolving data. We structure projects around milestone discussions so that the client can review findings, consider candidate quality, and make informed decisions about the next stage.
This collaborative approach is particularly valuable for complex targets and programs with functional requirements.
A small biotechnology company may need a complete development pathway, while an established organization may need support for one specific stage. Project scope can be aligned with the available internal resources, existing assays, target materials, and downstream plan.
Precision Antibody does not operate a laboratory or office in Cambridge. We support Cambridge and Greater Boston research teams from our facility in Columbia, Maryland.
This geographic clarity is important. It allows clients to understand where laboratory work is performed while benefiting from remote scientific collaboration and coordinated project management.
Initial discussions can cover:
These discussions can be conducted remotely with the relevant scientific and project stakeholders.
Project milestones provide natural points for reviewing immune response data, screening results, candidate quality, assay findings, and next-step recommendations.
A milestone-based approach helps the client understand what has been completed, what the data show, and what decision is required before advancing.
Samples, antigens, controls, clones, purified antibodies, sequence files, and project reports can be coordinated according to the agreed project plan. Shipping requirements, storage conditions, material quantities, and transfer details should be addressed before the relevant stage.
All antibody development work is performed at our Columbia, Maryland facility. Cambridge references on this page describe the organizations and research teams we serve, not a Precision Antibody physical location in Massachusetts.
A productive project discussion begins with a clear understanding of the research need. Cambridge teams preparing to outsource fully human monoclonal antibody development should consider the following questions.
Define whether the antibody needs to bind, block, activate, internalize, neutralize, detect, capture, or distinguish a specific target form.
Identify the assays, controls, thresholds, and comparison criteria that will be used to evaluate candidates.
Review the antigen format, sequence, purity, concentration, storage condition, and relevance to the native target.
Determine whether the antibody should recognize or avoid related proteins, species homologs, isoforms, mutants, or family members.
Decide whether the program requires hybridoma clones, purified antibodies, sequences, recombinant material, affinity data, functional results, cell banks, or production quantities.
The project should generate the information needed for a specific next step, such as target validation, lead selection, assay development, mechanism studies, or preclinical research.
Precision Antibody offers an approximately 60-day development pathway for suitable fully human monoclonal antibody projects. The exact timing depends on antigen readiness, the immune response, screening complexity, functional assay requirements, clone confirmation, and the agreed endpoint.
During project planning, we define what the timeline is expected to include. Additional characterization, recombinant expression, stability work, or larger-scale production may continue beyond the initial development period.
We use TC mouse technology to generate fully human IgG responses following immunization with an appropriate antigen. Antibody-producing cells are then used for hybridoma generation, followed by screening, cloning, candidate selection, sequencing, and agreed characterization.
The resulting antibodies contain human immunoglobulin sequences. Their suitability for a specific research program still depends on binding, specificity, function, expression, stability, and other candidate properties.
No. Precision Antibody performs laboratory work at its facility in Columbia, Maryland.
We serve Cambridge biotech, biopharmaceutical, academic, diagnostic, and translational research teams through remote scientific consultation, milestone reviews, project management, data communication, and coordinated transfer of materials and deliverables. The Cambridge focus describes the market and research community we support, not a physical Precision Antibody location.
Yes. Antibody development projects can be planned and managed remotely. Scientific teams can discuss the target, antigen, intended function, screening requirements, controls, timeline, and deliverables before work begins.
During the project, data and milestone findings can be reviewed with the client so that decisions are made collaboratively. Laboratory activities remain in Columbia, Maryland, while project communication can involve stakeholders throughout Cambridge and Greater Boston.
Under applicable project agreements, developed clones are transferred to the customer, and Precision Antibody does not retain ownership of the completed clones.
The exact ownership, confidentiality, delivery, and use terms are governed by the executed agreement. These terms should be reviewed before the project begins, particularly when the antibodies may support proprietary targets, therapeutic research, platform development, or future intellectual property.
Yes, functional screening may be included when a suitable assay, required materials, and agreed project scope are available.
Functional evaluation may address neutralization, inhibition, internalization, agonistic activity, cell binding, pathway effects, or another relevant biological outcome. The assay should reflect the intended use of the antibody. Functional screening requirements are best discussed during project design because they can affect materials, controls, timing, and candidate selection.
Antibody candidates can be evaluated using binding, specificity, and kinetic methods appropriate to the project. Affinity and binding kinetics may be measured using platforms such as Octet or Biacore.
Specificity assessment may include related proteins, species homologs, target-negative controls, alternate antigen formats, or cell-based confirmation. The most informative characterization plan combines affinity data with relevant specificity and functional results.
Yes. Selected antibodies can be produced and purified for research, characterization, assay development, and preclinical evaluation. Production may range from smaller quantities to gram-scale material, depending on the antibody, expression system, purity requirements, and project scope.
Recombinant expression may also be used to confirm sequence-defined candidates or generate material in a selected format. Production timelines are established separately from the initial discovery schedule when necessary.
A useful first discussion includes the target name, biological context, available antigen, intended antibody function, desired species reactivity, screening assays, controls, timeline, and required deliverables.
It is also helpful to identify any known target challenges, such as low expression, high conservation, membrane localization, conformational sensitivity, or previous unsuccessful antibody campaigns. This information allows us to evaluate feasibility and recommend a more relevant development strategy.
No. Precision Antibody products and services are intended for research use. They are not supplied for direct therapeutic, diagnostic, investigational, or clinical use.
Antibodies generated through our services may support discovery and preclinical research, but additional engineering, developability assessment, manufacturing development, quality systems, safety testing, regulatory work, and clinical evaluation would be required before any therapeutic or diagnostic application.
A fully human monoclonal antibody project should begin with the research objective, not a standard package. The target, antigen, assay, functional requirement, desired candidate profile, timeline, and downstream plan all influence how the program should be designed.
Precision Antibody works with Cambridge biotech and biopharmaceutical teams that need focused scientific support, application-specific screening, defined project milestones, and clear ownership of developed clones. Our laboratory work is performed in Columbia, Maryland, with remote consultation and project coordination available for research teams throughout Cambridge and Greater Boston.
To prepare for an initial discussion, gather the available target information, antigen details, assay requirements, desired function, relevant controls, timeline, and expected deliverables. We can then evaluate the project and define a development pathway aligned with the decisions your team needs to make next.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
